In people with HF, CKD, established CVD or multiple risk factors for CVD, the decision to use a GLP-1 RA or SGLT2i with proven benefit should be independent of background use of metformin
Semaglutide data tells a similar story
Offer stepwise titration and informed consent that includes potential pro-growth risks
For primary weight management, the NICE overweight and obesity management guideline takes precedence
Under ad libitum feeding conditions, we found that heart, body, and heart/body weights and nonfasting tail blood glucose measurements were not affected by treatment assignment (Supplemental Figure 1
Extensive Clinical Application of GLP-1RAs GLP-1RAs for the Treatment of T2DM GLP-1RAs are well established for the management of T2DM, and their clinical efficacy has been extensively investigated and validated